🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I've been hearing a lot about this common concern: "Are kids getting too many vaccines?" It's a fair question. I'm a parent too. And as an infectious diseases physician who directs an antibiotic stewardship program, a big part of my job is stopping unnecessary medications. I'm

There are a couple of limitations of Sana’s clinical stage islet cell program: 1) This program utilizes cadaveric cells (not scalable) 2) what is the c-peptide level? The data in Jan showed ~17 pmol/L after MMTT — normal would be close to 1,000 Good start but a long way to go.

Autism Rates Have Increased 60-Fold. I Played a Role in That. nytimes.com/2025/06/23/opi… via @NYTOpinion

statnews.com/2025/05/27/bio…

$HIMS — $NVO, $XBI From Biotech Hangout, hard to better summarize the zero value add proposition of $HIMS in GLP-1s than this: Tim Opler: The original deal was sort of weird, because you can go buy semaglutide directly from $NVO, from their direct website, and $HIMS was literally

11.8 million people could lose health insurance under Senate GOP tax bill statnews.com/2025/06/29/11-…

$RVMD $SMMT Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinati... - SMMT • BioPharmCatalyst biopharmcatalyst.com/company/SMMT/n…

Consistent with many young people not knowing they have high cholesterol, many young people with high cholesterol are not currently on a lipid lowering medication. This is not good, since it means they're likely accruing cardiovascular damage.

(1/3) Wow, second half of the year already? Here are some catalysts for 3Q25! Those in 4Q25 are not listed. The ones in the nice, calming blue are those I have my eye on! $ABUS $ABVX $AMLX $APGE $ATYR $CAPR $COGT $CRDF $FULC $KALA $MLTX $NEUP $OMER $RARE $REPL $SRRK $VYNE

Lacks a comparator group. Most people with a deficiency in the table just have low Vitamin D. What’s the rate of Vitamin D deficiency in a comparable population not treated with GLP1? Probably very high.

An excellent new article published survival curves for the 1750s and the 2010s, and the difference could not be more stark. You can really see the incredible contributions of reductions in early life mortality to the increase in life expectancies.

The facts are simple and devastating: Aid cuts have already cost lives, and the number of deaths will continue to rise. Here’s the evidence.

As a CEO, the day to day work and mission (patients, team) is really rewarding and what drives so many of us. With that said, I sometimes see colleagues lose sight of the fact that we need to deliver what we promised to shareholders. What you told them you would do as close as

Day #347 -- Merkel cell carcinoma log. There is a persistent insistence on offering best case scenarios in cancer care. “You’re doing great,” the go-to answer in the movies when you’re bleeding out from a mortal wound, is the daily reality for cancer patients. I’ve heard it from

Milei ended rent freezes in Argentina: Mortgage costs went down by 30% Rent prices went down by 26% Housing supply is up 212% Funny how that works

Nice visual representation of China's current advantage in patient recruitment / trial enrollment Oncology & Obesity Ph1s & 2s enroll 6-9 months faster in China than in the US H/t Bloomberg

Interesting that even in the latest data tirzepatide discontinuations are similar to sema The fact is GLP1s (alone or in combo) are not drugs for chronic use. But obesity and its clinical sequelae are chronic diseases The opportunity for new MoAs is immense

Agreed—the startup process is more onerous and so is downsizing or winding down a company. It’s not an entrepreneur friendly environment.

The crucial difference with CAR-T is those approved drugs actually work.

Alarming article about overly aggressive organ procurement. I believe these cases represent a tiny fraction of organ donations but they cast a shadow on the whole effort. nytimes.com/2025/07/20/us/… via @NYTimes